慢性淋巴细胞白血病的分子生物学驱动的前线治疗:随机临床试验的网络元分析
Andrea Rizzuto1, Angelo Pirrera1, Emilia Gigliotta1
1Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, 90141 Palermo, Italy.
International journal of molecular sciences
|June 28, 2023
概括
在第一线慢性淋巴细胞白血病 (CLL) 治疗中,非化疗方案,特别是与acalabrutinib结合的obinutuzumab,是首选方案. 网络分析表明,这些组合比传统的化疗-免疫疗法具有更高的疗效和安全性.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床药理学 临床药理学
背景情况:
- 目前的慢性淋巴细胞白血病 (CLL) 治疗包括化学免疫疗法,布鲁顿的氨酸激酶 (BTK) 抑制剂或BCL2抑制剂,通常与抗CD20单克隆抗体相结合.
- 由于多种第一线选择和有限的对比,治疗选择具有挑战性.
结论:
- 建议使用无化疗方案,如奥比努图祖马布加上阿卡拉布鲁替尼,作为CLL首线治疗的首选方案,不论其分子特征如何.
- 化疗在CLL一线治疗中的作用正在减少.
相关概念视频
Combination Therapies and Personalized Medicine
5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


